| Literature DB >> 33029095 |
Haozhen Ma1,2, Jianmao Zheng1,2, Xiaolan Li1,2.
Abstract
Background: Some studies have reported biological linkages between periodontitis and esophageal cancer, prostate cancer, kidney cancer, hematological malignancy, and melanoma of the skin. This meta-analysis aimed to assess the relationship between periodontitis and the aforementioned five cancers.Entities:
Keywords: Esophageal cancer; hematological malignancy; melanoma of the skin; meta-analysis; periodontitis; prostate cancer
Mesh:
Year: 2020 PMID: 33029095 PMCID: PMC7532473 DOI: 10.7150/ijms.46812
Source DB: PubMed Journal: Int J Med Sci ISSN: 1449-1907 Impact factor: 3.738
Classification of periodontitis severity
| Periodontitis Severity | ||
|---|---|---|
| Classification criteria* | Mild/Moderate | Severe |
| AL or/and PD | at least two teeth with interproximal AL ≥4 mm or at least two teeth with interproximal PD ≥5 mm | at least two teeth with interproximal AL ≥6 mm and at least one tooth with interproximal PD ≥5 mm |
| AL | >10% to <30% of examined sites (six sites on all teeth) having AL>3 mm | >30% of examined sites (six sites on all teeth) with AL>3 mm |
| ACH or/and tooth loss | whole mouth mean ACH ≥2mm to <3mm, or at least one site ACH ≥4mm, and no tooth loss due to periodontitis | whole mouth mean ACH ≥ 3mm, or at least two sites ACH ≥5mm, or tooth loss due to periodontitis |
AL: attachment loss; ACH: alveolar crestal height; PD: probing depth;
*It can be considered as mild/moderate periodontitis by meeting any one of the criteria of mild/moderate. The same is true for severe.
Summary of the enrolled studies
| Research ID | Author year | Origin | Study design | Mean follow-up period (yrs) | Mean age | Sex | Sample size | Periodontitis assessment | Severity of periodontitis | Cancer assessment | Cancer types | NOS scores |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| #1 | Chung 2016 | China | Retrospective cohort | 5 | 54.1 | Both | 80,280 | At least two consensus diagnoses | Unspecified | Ambulatory care claims code | Hematological malignancy, etc. | 7 |
| Lee 2014 | China | Retrospective cohort | 8.425 | 39.8 | Both | 718,409 | At least two consensus diagnoses | Dental prophylaxis group; Intensive treatment groupa; PD without treatment group. | Ambulatory care claims code | Esophagus, etc. | 7 | |
| #2 | Nwizu 2017 | America | Prospective cohort | 8.32 | 68.3 | Female | 65,869 | Self-report | Unspecified | Medical records | Esophagus, Kidney, Hematological malignancy, Melanoma of the skin, etc. | 6 |
| #3 | Michaud 2018 | America | Prospective cohort | 14.7 | 62.5 | Both | 6,056 | Clinical diagnosis | No/mild; Moderate; Severe | State cancer registries | Prostate, Hematological malignancy, etc. | 8 |
| #4 | Mai 2016 | America | Prospective cohort | 12.2±4.2 | 66.7 | Female | 1,337 | Defined by alveolar crestal height | Mild/ moderate; Severe | Medical records | Melanoma of the skin, Hematological malignancy, etc. | 7 |
| #5 | Michaud 2008 | America | Prospective cohort | 17.7 | 54.42 | Male | 48,375 | Radiographs for bone loss assessment | Unspecified | Medical records or pathology reports | Esophagus, Kidney, Hematological malignancy, etc. | 7 |
| Michaud 2016 | America | Prospective cohort | 26 | 52.89 | Male | 19,933 | Radiographs for bone loss assessment | Unspecified | Medical records or pathology reports | Prostate, Melanoma of the skin, etc. | 7 | |
| #6 | Arora 2010 | Sweden | Prospective cohort | 27 | 51 | Both | 15,333 | Self-report teeth mobility | Minor mobility; Periodontal disease | Records in cancer register | Prostate, etc. | 7 |
| #7 | Lee 2017 | South Korea | Retrospective cohort | 12 | 61.2 | Both | 187,934 | Clinical and radiographic diagnoses | Unspecified | diagnostic codes | Prostate, etc. | 6 |
| #8 | Ahn 2012 | America | Prospective cohort | unreported | 38.99 | Both | 12,605 | Periodontal attachment loss and pocket depth | Unspecified | Mortality File | Esophagus, etc. | 6 |
CI: confidence interval; NOS: Newcastle-Ottawa scale;
a For example, subgingival scaling, gingivectomy, periodontal flap surgery.
Adjusted covariates in studies included in the meta-analysis
| Study | Adjusted covariates |
|---|---|
| Chung 2016 | Age, sex, urbanization, salary, location |
| Lee 2014 | Age, sex, drinking status, comorbidities of esophageal malignancy |
| Nwizu 2017 | Age, education, geographic location, tobacco consumption, family history of malignant tumors, exercise habit, secondhand cigarette smoke, drinking status, fruit and vegetable intake |
| Michaud 2018 | Age, location, educational status, alcohol consumption, blood glucose level, BMI, race, smoking behaviors |
| Mai 2016 | Age, oral hygiene habits, family history of malignant tumors, educational status, tobacco consumption, secondhand cigarette smoke, body mass index |
| Michaud 2008 | Age, frequency of exercise, BMI, energy intake, dietary collocation, drinking status, tobacco consumption, blood glucose level, smoking behaviors, calcium supplement, residence, race |
| Michaud 2016 | Age, drinking habit, tobacco consumption, height, frequency of exercise, BMI, residence region |
| Arora 2010 | Age, gender, blood glucose level, tobacco consumption, tobacco consumption of partner, drinking behavior, BMI, vocation, education |
| Lee 2017 | Age, sex, family economic status, location, cardiovascular and cerebrovascular diseases, physical activity, drinking habit, tobacco consumption |
| Ahn 2012 | Sex, age , ethnic origin, smoking status, education |
BMI: Body mass index.
Results of overall estimates
| Cancer | No. of studies | Heterogeneity | Model | Meta-analysis | |||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | ||||||
| Esophageal | 4 | 60% (0%-87%) | 0.06 | Random | 1.79 | 1.15-2.79 | 0.009 |
| Prostate | 4 | 0% (0%-85%) | 0.60 | Random | 1.20 | 1.09-1.31 | 0.0002 |
| Kidney | 2 | 44% (0%-84%) | 0.18 | Random | 1.30 | 0.96-1.76 | 0.09 |
| Hematological | 5 | 0% (0%-79%) | 0.61 | Random | 1.19 | 1.09-1.29 | <0.0001 |
| Melanoma of the skin | 3 | 0% (0%-90%) | 0.70 | Random | 1.21 | 1.03-1.42 | 0.02 |
No. of studies: the number of studies.
Subgroup analysis of studies on periodontitis and esophageal cancer
| Subgroup | No. of studies | Heterogeneity | Model | Meta-analysis | |||
|---|---|---|---|---|---|---|---|
| HR | 95%CI | ||||||
| Overall analysis | 4 | 60% (0%-87%) | 0.06 | Random | 1.79 | 1.15-2.79 | 0.009 |
| Medium | 2 | 0% | 0.85 | Random | 3.37 | 1.83-6.22 | <0.0001 |
| High | 2 | 0% | 0.65 | Random | 1.35 | 1.04-1.75 | 0.03 |
| <50 | 2 | 59% (0%-90%) | 0.12 | Random | 1.81 | 0.67-4.88 | 0.24 |
| ≥50 | 2 | 71% | 0.06 | Random | 2.12 | 1.01-4.45 | 0.05 |
| Male | 2 | 0% | 0.88 | Random | 1.41 | 1.08-1.83 | 0.01 |
| Female | 2 | 75% (0%-94%) | 0.05 | Random | 1.37 | 0.17-11.02 | 0.77 |
| With smoking status | 3 | 63% (0%-89%) | 0.07 | Random | 2.28 | 1.16-4.49 | 0.02 |
| With socio-economic status | 2 | 0% | 0.85 | Random | 3.37 | 1.83-6.22 | <0.0001 |
No. of studies: the number of studies.
Subgroup analysis of studies on periodontitis and prostate cancer
| Subgroup | No. of studies | Heterogeneity | Model | Meta-analysis | |||
|---|---|---|---|---|---|---|---|
| HR | 95%CI | ||||||
| Overall analysis | 4 | 0% (0%-85%) | 0.60 | Random | 1.20 | 1.09-1.31 | 0.0002 |
| Periodontitis severity | |||||||
| Mild/moderate | 2 | 0% | 0.41 | Random | 1.14 | 0.95-1.37 | 0.17 |
| Severe | 2 | 0% | 0.48 | Random | 1.34 | 1.06-1.68 | 0.01 |
| Adjusted covariates | |||||||
| With smoking status | 4 | 0% (0%-85%) | 0.60 | Random | 1.20 | 1.09-1.31 | 0.002 |
| With socio-economic status | 3 | 0% (0%-58%) | 0.40 | Random | 1.20 | 1.08-1.33 | 0.0007 |
| Mean age | |||||||
| ≤60 | 2 | 11% (0%-43%) | 0.29 | Random | 1.26 | 1.03-1.54 | 0.02 |
| >60 | 2 | 0% | 0.53 | Random | 1.18 | 1.05-1.31 | 0.001 |
| Sample size | |||||||
| ≤15000 | 2 | 0% | 0.42 | Random | 1.30 | 1.09-1.55 | 0.004 |
| >15000 | 2 | 0% | 0.87 | Random | 1.16 | 1.03-1.29 | 0.01 |
No. of studies: the number of studies.
Subgroup analysis of studies on periodontitis and HM
| Subgroup | No. of studies | Heterogeneity | Model | Meta-analysis | |||
|---|---|---|---|---|---|---|---|
| HR | 95%CI | ||||||
| Overall analysis | 5 | 0% (0%-79%) | 0.61 | Random | 1.19 | 1.09-1.29 | <0.0001 |
| <60 | 2 | 0% | 0.38 | Random | 1.23 | 1.11-1.37 | 0.0001 |
| ≥60 | 3 | 0% (0%-90%) | 0.75 | Random | 1.11 | 0.96-1.28 | 0.15 |
| Male | 2 | 0% | 0.38 | Random | 1.33 | 1.14-1.54 | 0.0003 |
| Female | 3 | 0% (0%-90%) | 0.51 | Random | 1.09 | 0.93-1.27 | 0.27 |
| Mild/moderate | 2 | 0% | 0.45 | Random | 1.08 | 071-1.65 | 0.73 |
| Severe | 2 | 0% | 0.50 | Random | 1.47 | 0.92-2.33 | 0.11 |
| With smoking status | 4 | 0% (0%-85%) | 0.45 | Random | 1.19 | 1.07-1.33 | 0.001 |
| With socio-economic status | 4 | 0% (0%-85%) | 0.82 | Random | 1.14 | 1.03-1.27 | 0.009 |
| Non-smokers | 3 | 0% (0%-90%) | 0.63 | Random | 1.30 | 1.14-1.48 | 0.0001 |
| ≤10 | 2 | 0% | 0.42 | Random | 1.13 | 1.02-1.26 | 0.02 |
| >10 | 3 | 0% (0%-90%) | 0.96 | Random | 1.29 | 1.12-1.48 | 0.0004 |
| <10000 | 2 | 0% | 1.00 | Random | 1.24 | 0.91-1.69 | 0.18 |
| ≥10000 | 3 | 23% (0%-70%) | 0.27 | Random | 1.18 | 1.07-1.31 | 0.001 |
| Leukemia | 2 | 0% | 0.38 | Random | 1.21 | 0.98-1.49 | 0.08 |
| Non-Hodgkin lymphoma | 2 | 44% (0%-85%) | 0.21 | Random | 1.20 | 1.01-1.43 | 0.04 |
| Multiple myeloma | 2 | 0% | 0.44 | Random | 1.17 | 0.89-1.54 | 0.27 |
No. of studies: the number of studies.